BSE Live
Prev. Close
Open Price
Bid Price (Qty.)
()
Offer Price (Qty.)
()
NSE Live
Jan 20, 15:54Prev. Close
24.72
Open Price
24.06
Bid Price (Qty.)
23.71 (53)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Balaxi Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | |
| Per Share Ratios | |||||
| Basic EPS (Rs.) | 0.50 | 1.56 | 0.63 | 1.70 | |
| Diluted EPS (Rs.) | 0.50 | 1.56 | 0.63 | 1.70 | |
| Cash EPS (Rs.) | 0.34 | 1.57 | 0.64 | 1.72 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 10.07 | 10.48 | 10.08 | 10.50 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 10.61 | 11.14 | 10.74 | 11.16 | |
| Dividend / Share(Rs.) | 0.30 | 1.00 | 0.90 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 0.41 | 2.04 | 0.95 | 0.89 | |
| PBDIT/Share (Rs.) | 0.53 | 2.28 | 0.88 | 2.05 | |
| PBIT/Share (Rs.) | 0.53 | 2.27 | 0.87 | 2.04 | |
| PBT/Share (Rs.) | 0.48 | 2.13 | 0.84 | 2.01 | |
| Net Profit/Share (Rs.) | 0.34 | 1.56 | 0.63 | 1.70 | |
| Profitability Ratios | |||||
| PBDIT Margin (%) | 131.32 | 111.61 | 92.82 | 229.95 | |
| PBIT Margin (%) | 129.98 | 111.35 | 91.93 | 228.65 | |
| PBT Margin (%) | 118.91 | 104.31 | 88.26 | 226.01 | |
| Net Profit Margin (%) | 82.71 | 76.71 | 66.69 | 191.20 | |
| Return on Networth / Equity (%) | 3.34 | 14.93 | 6.26 | 16.23 | |
| Return on Capital Employed (%) | 3.17 | 14.04 | 5.87 | 11.97 | |
| Return on Assets (%) | 2.78 | 9.09 | 3.57 | 10.14 | |
| Total Debt/Equity (X) | 0.00 | 0.25 | 0.00 | 0.29 | |
| Asset Turnover Ratio (%) | 3.36 | 11.85 | 5.35 | 5.30 | |
| Liquidity Ratios | |||||
| Current Ratio (X) | 0.58 | 2.42 | 1.58 | 4.71 | |
| Quick Ratio (X) | 0.58 | 2.42 | 1.58 | 4.71 | |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (NP) (%) | 89.10 | 63.91 | 142.49 | 58.66 | |
| Dividend Payout Ratio (CP) (%) | 87.67 | 63.69 | 140.60 | 58.27 | |
| Earnings Retention Ratio (%) | 10.90 | 36.09 | -42.49 | 41.34 | |
| Cash Earnings Retention Ratio (%) | 12.33 | 36.31 | -40.60 | 41.73 | |
| Valuation Ratios | |||||
| Enterprise Value (Cr.) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Retention Ratios (%) | 10.89 | 36.08 | -42.49 | 41.33 | |
| Price/BV (X) | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/Net Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | 0.00 | 0.00 | 0.00 | 0.00 |
19.11.2025
Balaxi Pharma Consolidated September 2025 Net Sales at Rs 56.18 crore, down 27.41% Y-o-Y
18.11.2025
Balaxi Pharma Standalone September 2025 Net Sales at Rs 19.31 crore, down 8.72% Y-o-Y
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
19.11.2025
Balaxi Pharma Consolidated September 2025 Net Sales at Rs 56.18 crore, down 27.41% Y-o-Y
18.11.2025
Balaxi Pharma Standalone September 2025 Net Sales at Rs 19.31 crore, down 8.72% Y-o-Y
12.08.2025
Balaxi Pharma Consolidated June 2025 Net Sales at Rs 70.74 crore, up 7.8% Y-o-Y
06.08.2025
Balaxi Pharma Standalone June 2025 Net Sales at Rs 16.71 crore, down 12.18% Y-o-Y
15.06.2017
24.04.2017
18.04.2017
18.04.2017
14.02.2017
13.02.2017
12.02.2017
09.12.2016